Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 6:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 1,706 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Human Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS) Clear all

Conditions: HIV-infection/Aids
Interventions: Cognitive-behavioral HIV/STD risk reduction; Behavioral
Lead sponsor: Mississippi State University; Other
Eligibility: 13 Years to 18 Years · Female only
Enrollment: 333 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Columbia, Mississippi

Conditions: Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions: Nelfinavir mesylate; Drug
Lead sponsor: Agouron Pharmaceuticals; Industry
Eligibility: 13 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 5
States / cities: San Diego, California • Torrance, California • Chicago, Illinois + 2 more

Conditions: HIV Infections
Interventions: Enfuvirtide T/20/Ro 29,9800, HIV-1 Infusion Inhibitor; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: Emtricitabine/ tenofovir disoproxil fumarate, Lopinavir/Ritonavir; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 25
States / cities: San Diego, California • San Francisco, California • Torrance, California + 16 more

Conditions: HIV Infection
Interventions: Observational Study; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 280 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 55
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 41 more

Conditions: HIV, Infectious
Interventions: darunavir, ritonavir; Drug
Lead sponsor: Tibotec, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 429 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 41
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 38 more

Conditions: Exposure to Human Immunodeficiency Virus (Event)
Interventions: Currently approved medications; Drug
Lead sponsor: Huntridge Family Clinic; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Mycoses, Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions: Azithromycin, Rifabutin, Fluconazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 720 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 12
States / cities: Los Angeles, California • Orange, California • San Diego, California + 7 more

Conditions: HIV, Human Immunodeficiency Virus
Interventions: PRO 140, Historical data; Drug · Other
Lead sponsor: CytoDyn, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Human Immunodeficiency Virus, Depression, Anxiety
Interventions: THRIVE, Treatment as Usual; Behavioral · Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 80 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: HIV/AIDS
Interventions: Not listed
Lead sponsor: Harvard School of Public Health (HSPH); Other
Eligibility: 18 Years and older
Enrollment: 818 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2025
U.S. locations: 13
States / cities: La Jolla, California • Aurora, Colorado • Fort Lauderdale, Florida + 9 more

Conditions: Infection, Human Immunodeficiency Virus
Interventions: BMS-955176, EFV, TDF/FTC; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 8
States / cities: Beverly Hills, California • Los Angeles, California • DeLand, Florida + 5 more

Conditions: Human Immunodeficiency Virus (HIV)
Interventions: DRV/COBI FDC; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 3 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: HIV Infections
Interventions: HIVAC-1e, gp160 Vaccine (MicroGeneSys); Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 60 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 1993
U.S. locations: 1
States / cities: Rochester, New York

Conditions: HIV Infections, Chronic Hepatitis B
Interventions: Adefovir Dipivoxil; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV I Infection
Interventions: Our Family, Our Voices; Behavioral
Lead sponsor: State University of New York - Downstate Medical Center; Other
Eligibility: 18 Years to 30 Years
Enrollment: 168 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Healthy
Interventions: TMC278, Long acting (LA); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Infection, Human Immunodeficiency Virus
Interventions: GSK1349572, Placebo; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 18
States / cities: Bakersfield, California • Long Beach, California • Newport Beach, California + 13 more

Conditions: HIV, Immunodeficiencies, Infectious Diseases
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 2,419 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 1993
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Bethesda, Maryland

Conditions: Human Immunodeficiency Virus (HIV), Human Papillomavirus (HPV)
Interventions: Perianal and Digital Anorectal Exam, Cervical Swabs, Anal Swabs, High Resolution Anoscopy (HRA); Procedure
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: HIV Associated Neurocognitive Disorder, Human Immunodeficiency Virus
Interventions: Not listed
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 59 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Hepatitis C, HIV Infections
Interventions: Peginterferon alfa-2b, Ribavirin; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2009
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: Zidovudine, Didanosine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1995
U.S. locations: 7
States / cities: Minneapolis, Minnesota • Saint Paul, Minnesota • Omaha, Nebraska + 3 more

Conditions: Infection, Human Immunodeficiency Virus I
Interventions: GSK1349572, GSK2248761; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Buffalo, New York

Search by objective public record fields.

Healthy Teen Girls: HIV Risk Reduction

A Study of Viracept in AIDS Patients With Mycobacterium Avium Complex Disease (MAC)

Fuzeon (Enfuvirtide) Early Access Program for Patients With HIV-1 Infection

Nine Month Course of Anti-HIV Medications for People Recently Infected With HIV

HLA-B*5701 And Hypersensitivity To Abacavir

GRACE: A Study to Compare the Effectiveness, Safety and Tolerability of PREZISTA (Darunavir)/Ritonavir by Gender and Race When Administered With Other Antiretroviral Medications in Human Immunodeficiency Virus (HIV) Positive Women and Men.

What Happens in Vegas: PEP to PrEP Opportunities

A Randomized Study of Daily and Intermittent Prophylactic Regimens for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) and Fungal Infections in HIV-Infected Patients

Treatment Substitution With PRO 140 Monotherapy in Adult Subjects With HIV-1 Infection

Targeting HIV Retention and Improved Viral Load Through Engagement ('THRIVE')

Adolescent Master Protocol for Participants 18 Years of Age and Older (AMP Up)

Dose-finding Study of BMS-955176 to Treat HIV-1 Infected Treatment-naive Adults

A Study to Assess the Acceptability of the Darunavir/Cobicistat (DRV/COBI) Fixed-dose Combination (FDC) Tablet in Human Immunodeficiency Virus (HIV)-1 Infected Children

A Phase I Multicenter, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of Recombinant Vaccinia Virus Expressing the Envelope Glycoproteins of Human Immunodeficiency Virus

Lamivudine and Adefovir to Treat Chronic Hepatitis B Infection in People With and Without HIV Infection

Leveraging Family-Based Assets for Black MSM In House Ball Communities

A Study to Evaluate Safety, Acceptability, Pharmacokinetics, and ex Vivo Pharmacodynamics of TMC278 Long Acting Formulation in HIV-1 Seronegative Participants

Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected Adults

Studies of the Pathogenesis of HIV Infection in Human Peripheral Blood Cells and/or Body Fluids in People Living With and Without HIV

New Strategies to Assess Anal Cancer Risk In Women

Observational Study of HIV-associated Neurocognitive Disorder

Peginterferon Alpha-2b And Ribavirin to Treat Hepatitis C in HIV-Infected Patients

The Effectiveness of Two Anti-HIV Treatments in HIV-Infected Patients

A Drug Interaction Study Evaluating Plasma GSK2248761 and GSK1349572 Pharmacokinetics in Healthy Adult Subjects.